Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668493 · ClinicalTrials.gov registry record · Phase 1
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
A Phase 1 study of Low-grade Upper Tract Urothelial Carcinoma, sponsored by Ferring Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT06668493: Recruiting Phase 1 study of Low-grade Upper Tract Urothelial Carcinoma, sponsored by Ferring Pharmaceuticals.
NCT06668493 is a Phase 1 study of Low-grade Upper Tract Urothelial Carcinoma that is actively recruiting participants, run by Ferring Pharmaceuticals. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06668493, a Phase 1 study of Low-grade Upper Tract Urothelial Carcinoma, is actively recruiting participants, sponsored by Ferring Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
Conditions Studied
Interventions
- DRUG Nadofaragene Firadenovec
Study Locations (7)
Arizona
- Mayo Clinic - Scottsdale Arizona - Scottsdale
Florida
- Mayo Clinic - Jacksonville
Indiana
- Indiana University - Indianapolis
Minnesota
- Mayo Clinic - Rochester Minnesota - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology - Philadelphia
Texas
- MD Anderson Cancer Center - Genitourinary (GU) Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 1 |
What NCT06668493 shows while recruiting
NCT06668493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Low-grade Upper Tract Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Nadofaragene Firadenovec is the first listed.
NCT06668493 lists 7 locations in 7 states (Arizona, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT06668493 about?
NCT06668493 is a clinical study titled "Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis". The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in ...
What is the current status of trial NCT06668493?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-12. Estimated completion is 2029-11-30.
What conditions does trial NCT06668493 study?
This clinical trial studies the following conditions: Low-grade Upper Tract Urothelial Carcinoma.
What interventions are being tested in trial NCT06668493?
The interventions under investigation include: Nadofaragene Firadenovec (DRUG).
Who is sponsoring clinical trial NCT06668493?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06668493 being conducted?
This trial has 7 study locations across Arizona, Florida, Indiana, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low-grade Upper Tract Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06668493's enrollment target sits among peer trials
20 1630th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI